These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34352992)

  • 21. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
    Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
    BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
    Nauck MA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
    Pinheiro MM; Fabbri A; Infante M
    Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DPP IV inhibitors: successes, failures and future prospects.
    Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
    Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [DPP-4 inhibitors, GLP-1 receptor agonists].
    Hamasaki A; Inagaki N
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():654-61. PubMed ID: 21766677
    [No Abstract]   [Full Text] [Related]  

  • 29. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T; Shimomura I
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19.
    Mahgoub S; Fatahala SS; Sayed AI; Atya HB; El-Shehry MF; Afifi H; Awad SM; El-Hameed RHA; Taha H
    Bioorg Chem; 2022 Nov; 128():106092. PubMed ID: 35985159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
    Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
    Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.
    Kushwaha RN; Haq W; Katti SB
    Curr Med Chem; 2014; 21(35):4013-45. PubMed ID: 25245373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
    Ramos-Rincón JM; Pérez-Belmonte LM; Carrasco-Sánchez FJ; Jansen-Chaparro S; De-Sousa-Baena M; Bueno-Fonseca J; Pérez-Aguilar M; Arévalo-Cañas C; Bacete Cebrian M; Méndez-Bailón M; Fiteni Mera I; González García A; Navarro Romero F; Tuñón de Almeida C; Muñiz Nicolás G; González Noya A; Hernández Milian A; García García GM; Alcalá Pedrajas JN; Herrero García V; Corral-Gudino L; Comas Casanova P; Meijide Míguez H; Casas-Rojo JM; Gómez-Huelgas R;
    J Gerontol A Biol Sci Med Sci; 2021 Jul; 76(8):e102-e109. PubMed ID: 33945610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of type 2 diabetes mellitus in chronic kidney disease.
    Maffioli P; Derosa G
    Curr Med Res Opin; 2015 Jan; 31(1):95-7. PubMed ID: 25325220
    [No Abstract]   [Full Text] [Related]  

  • 38. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus
.
    Suzuki Y; Tanaka A; Tanaka M; Hidaka N; Miyake T; Matsuura B; Hiasa Y; Araki H
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):474-477. PubMed ID: 31232277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.